Stemline Therapeutics, Inc. (STML): Price and Financial Metrics
STML Price/Volume Stats
Current price | $11.83 | 52-week high | $18.22 |
Prev. close | $12.00 | 52-week low | $3.21 |
Day low | $11.82 | Volume | 17,354,300 |
Day high | $12.10 | Avg. volume | 1,524,566 |
50-day MA | $8.63 | Dividend yield | N/A |
200-day MA | $8.77 | Market Cap | 621.21M |
STML Stock Price Chart Interactive Chart >
Stemline Therapeutics, Inc. (STML) Company Bio
Stemline Therapeutics is a clinical stage biopharmaceutical company developing novel therapeutics that target cancer stem cells (CSCs) and tumor bulk. The company was founded in 2003 and is based in New York, New York.
Latest STML News From Around the Web
Below are the latest news stories about Stemline Therapeutics Inc that investors may wish to consider to help them evaluate STML as an investment opportunity.
Stemline Therapeutics acquired by Menarini GroupMenarini Group completed acquisition of Stemline Therapeutics (STML) for aggregate cash consideration up to $677M. Details here.Through the acquisition, Menarini's U.S. presence would be established and it will enable global expansion by leveraging its commercial infrastructure in Europe and other geographies.Acquisition to bolster Menarini’s oncology portfolio with the addition of both commercial... |
Lifshitz Law Firm, P.C. Announces Investigation of Franklin Financial Network, Inc., Mobile Mini, Inc., Portola Pharmaceuticals, Inc., resTORbio, Inc., Stemline Therapeutics, Inc., Taubman Centers, Inc. and Willis Towers Watson Public Limited Company and Wright Medical Group N.V.Franklin Financial Network, Inc. (FSB) |
SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, and QES Shareholders About Its Ongoing InvestigationsNEW YORK, May 21, 2020 -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice. |
NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: QUINTANA ENERGY SERVICES, INC. (NYSE - QES), STEMLINE THERAPEUTICS, INC. (NASDAQ - STML) AND resTORbio, Inc. (NasdaqGS - TORC)BALA CYNWYD, PA / ACCESSWIRE / May 19, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other ... |
STEMLINE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of STML and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Stemline Therapeutics, Inc. (STML) breached their fiduciary duties or violated the federal securities laws in connection with the company’s proposed merger with Menarini Group. On May 4, 2020, Stemline announced that it had signed an agreement to be acquired by Menarini for up to $677 million through a tender offer effected by certain Menarini affiliates. According to the merger agreement, Stemline’s stockholders will receive $11.50 in cash and the chance to receive an additional $1.00 per share upon the first sale of ELZONRIS in any EU5 country after European Commission approval. |
STML Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | N/A |
3-year | N/A |
5-year | -7.94% |
YTD | N/A |
2023 | N/A |
2022 | N/A |
2021 | N/A |
2020 | 0.00% |
2019 | 11.89% |
Continue Researching STML
Here are a few links from around the web to help you further your research on Stemline Therapeutics Inc's stock as an investment opportunity:Stemline Therapeutics Inc (STML) Stock Price | Nasdaq
Stemline Therapeutics Inc (STML) Stock Quote, History and News - Yahoo Finance
Stemline Therapeutics Inc (STML) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...